Immunotherapy News and Research

Latest Immunotherapy News and Research

Research upends understanding of circadian clock in melanoma

A Ludwig Cancer Research study has found that the circadian clock-;which synchronizes physiological and cellular activities with the day-night cycle and is generally thought to be tumor suppressive-;in fact has a contextually variable role in cancer.

27 Jan 2024

A certain type of chemotherapy found to improve the immune system's ability to fight off bladder cancer

Tisch Cancer Institute researchers discovered that a certain type of chemotherapy improves the immune system's ability to fight off bladder cancer, particularly when combined with immunotherapy, according to a study published in Cell Reports Medicine in January.

27 Jan 2024

New insights into why immunotherapy works for some cancers, not others

A multi-institutional study co-authored by University of Texas at Arlington scientists uncovered a mechanism by which cancer cells prevent the immune system from activating and attacking the cancerous invaders.

24 Jan 2024

Penn analysis shows low risk of secondary cancers following CAR T cell therapy

The development of any type of second cancer following CAR T cell therapy is a rare occurrence, as found in an analysis of more than 400 patients treated at Penn Medicine, researchers from the Perelman School of Medicine at the University of Pennsylvania reported today in Nature Medicine.

24 Jan 2024

New workflow identifies shared cancer targets, advancing immunotherapy

Researchers developed the Splicing Neo Antigen Finder (SNAF) workflow, integrating deep learning to identify shared immunogenic neoantigens in cancers, offering new targets for cancer immunotherapy, particularly in melanoma and ovarian cancer.

23 Jan 2024

LTBR identified as potential target for cancer immunotherapy and marker of poor prognosis

A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 1, entitled, "Systematic analysis of the prognostic value and immunological function of LTBR in human cancer."

23 Jan 2024

Cleveland Clinic and IBM researchers reveal strategy for identifying new immunotherapy targets through AI

Researchers from Cleveland Clinic and IBM have published a strategy for identifying new targets for immunotherapy through artificial intelligence (AI).

23 Jan 2024

Long COVID and ME/CFS patients could benefit from a coordinated treatment strategy

People suffering from Long COVID or Myalgic Encephalomyelitis /Chronic Fatigue Syndrome (ME/CFS) could benefit from a coordinated treatment strategy, a new University of Otago study has found.

22 Jan 2024

COST Action bridges the gap in cancer immunotherapy research

Cancer is still a leading cause of death worldwide. Globally, there were an estimated 20 million new cases of cancer and 10 million deaths.

20 Jan 2024

Ludwig scientists deconstruct the blood supply of brain metastases

A Ludwig Cancer Research study has generated a granular portrait of how the cellular and molecular components of the blood vessels that feed brain metastases of melanoma and lung and breast cancers differ from those of healthy brain tissue, illuminating how they help shape the internal environment of tumors to support cancer growth and immune evasion.

19 Jan 2024

Annexin-A1 targeted therapy beats several cancers

A new study published in Nature's cancer journal Oncogene highlights the effectiveness of MDX-124, the first therapeutic drug to target annexin-A1, a protein which is overexpressed in several cancer types and promotes tumour progression.

19 Jan 2024

New targeted therapy eliminates cancer with zero side effects

Johannes Karges develops anti-cancer agents that work in a targeted manner, rather than adversely affecting the entire body.

18 Jan 2024

New bioengineered strategy shows potential for treating ulcerative colitis

By taking advantage of mechanisms that allow cancer cells to evade immune attack, UT Southwestern Medical Center researchers have developed a new strategy in animal models that has potential for treating ulcerative colitis.

17 Jan 2024

Innovative computational tool unearths hidden cancer targets for immunotherapy

An innovative computational tool dubbed "SNAF" may help the research world bring the emerging promise of cancer immunotherapy to a wider range of patients, according to a study published Jan. 17, 2024, in Science Translational Medicine.

17 Jan 2024

RBMX protein emerges as key player in cancer progression and immunotherapy response

A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 1, entitled, "Aberrant RBMX expression is relevant for cancer prognosis and immunotherapy response."

17 Jan 2024

Decoding blood cancer secrets to optimize CAR T therapy

Chimeric antigen receptor T-cell therapy, or CAR T, has dramatically improved the treatment of certain blood cancers. Initially approved for patients who had failed multiple lines of therapy, clinical trials have shown CAR T can be used as an earlier treatment option.

17 Jan 2024

Breakthrough nano-shield blocks selective allergic reactions

Northwestern University researchers have developed the first selective therapy to prevent allergic reactions, which can range in severity from itchy hives and watery eyes to trouble breathing and even death.

16 Jan 2024

Nanobots for bladder cancer treatment, promising high efficacy and targeted delivery

A study in Nature Nanotechnology reveals the potential of urease-powered nanobots to enhance bladder cancer treatment, showing a 90% tumor reduction in a mouse model using radioiodine-loaded nanobots for targeted therapy.

15 Jan 2024

Study explores intratumoral microbiota as a novel frontier in cancer research

Researchers review the role of intratumoral microbiota in cancer development, suggesting its potential in predicting and treating various cancers.

14 Jan 2024

Radiation and chemo combo tackles advanced non-small cell lung cancer

A new study led by researchers from the UCLA Health Jonsson Comprehensive Cancer Center shows that using high doses of radiation while integrating an ablative radiotherapy technique called stereotactic ablative radiotherapy (SABR) concurrently with chemotherapy is safe and effective in treating people with locally advanced non-small cell lung cancer that is not suitable for surgery.

11 Jan 2024